4.8 Article

Fibulin-5 Suppresses Lung Cancer Invasion by Inhibiting Matrix Metalloproteinase-7 Expression

Journal

CANCER RESEARCH
Volume 69, Issue 15, Pages 6339-6346

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-09-0398

Keywords

-

Categories

Funding

  1. NIH [CA106348, CA121105, CA129829, GM065188]
  2. American Lung Association
  3. American Cancer Society [RSG-07-156-01-CNE]
  4. Developmental Research Program
  5. Career Development Award
  6. Lung Cancer Specialized Program of Research Excellence at the University of Pittsburgh Cancer Institute [CA090440]
  7. Flight Attendant Medical Research Institute
  8. Alliance for Cancer Gene Therapy
  9. National Basic Research Program of China [2009CB521702]

Ask authors/readers for more resources

The high mortality rate of lung cancer is largely due to the spread of disease to other organs. However, the molecular changes driving lung cancer invasion and metastasis remain unclear. In this study, we identified fibulin-5, a vascular ligand for integrin receptors, as a suppressor of lung cancer invasion and metastasis. Fibulin-5 was silenced by promoter hypermethylation in a majority of lung cancer cell lines and primary tumors. It inhibited lung cancer cell invasion and down-regulated matrix metalloproteinase-7 (MMP-7), which promoted lung cancer cell invasion. Knockdown of fibulin-5 was sufficient to stimulate cell invasion and MMP-7 expression. The expression levels of fibulin-5 and MMP-7 were inversely correlated in lung tumors. Suppression of MMP-7 expression by fibulin-5 was mediated by an integrin-binding RGD motif via the extracellular signal-regulated kinase (ERK) pathway. Furthermore, overexpression of fibulin-5 in H460 lung cancer cells inhibited metastasis in mice. Collectively, these results suggest that epigenetic silencing of fibulin-5 promotes lung cancer invasion and metastasis by activating MMP-7 expression through the ERK pathway. [Cancer Res 2009;69(15):6339-46]

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

CDK4/6 Inhibition Suppresses p73 Phosphorylation and Activates DR5 to Potentiate Chemotherapy and Immune Checkpoint Blockade

Jingshan Tong, Xiao Tan, Xiangping Song, Man Gao, Denise Risnik, Suisui Hao, Kaylee Ermine, Peng Wang, Hua Li, Yi Huang, Jian Yu, Lin Zhang

Summary: This study found that CDK4/6 inhibitors promote immunogenic cell death of cancer cells by regulating the expression of p73 and DR5, enhancing the effects of chemotherapy and immune therapy.

CANCER RESEARCH (2022)

Article Oncology

tRF3008A suppresses the progression and metastasis of colorectal cancer by destabilizing FOXK1 in an AGO-dependent manner

Ying Han, Yinghui Peng, Shanshan Liu, Xinwen Wang, Changjing Cai, Cao Guo, Yihong Chen, Le Gao, Qiaoqiao Huang, Min He, Edward Shen, Jie Long, Jian Yu, Hong Shen, Shan Zeng

Summary: The expression of tRF3008A is reduced in colorectal cancer and is significantly correlated with advanced and metastatic disease. Patients with low tRF3008A expression have a shorter disease-free survival, and tRF3008A is regarded as an independent prognostic biomarker in colorectal cancer. Functionally, tRF3008A suppresses the proliferation and migration of colorectal cancer by inhibiting the expression of FOXK1.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Article Biochemistry & Molecular Biology

Intestinal Radiation Protection and Mitigation by Second-Generation Probiotic Lactobacillus-reuteri Engineered to Deliver Interleukin-22

Alexis Espinal, Michael W. Epperly, Amitava Mukherjee, Renee Fisher, Donna Shields, Hong Wang, M. Saiful Huq, Diala Fatima Hamade, Anda M. Vlad, Lan Coffman, Ronald Buckanovich, Jian Yu, Brian J. Leibowitz, Jan-Peter van Pijkeren, Ravi B. Patel, Donna Stolz, Simon Watkins, Asim Ejaz, Joel S. Greenberger

Summary: Gavaging Lactobacillus reuteri-Interleukin-22 (LR-IL-22) improves the delivery of IL-22 to the irradiated intestine and effectively mitigates radiation damage. Compared to the control group, gavaging LR-IL-22 improves multiple biomarkers associated with radiation damage.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Biology

Lactobacillus reuteri Releasing IL-22 (LR-IL-22) Facilitates Intestinal Radioprotection for Whole-Abdomen Irradiation (WAI) of Ovarian Cancer

Diala F. Hamade, Alexis Espinal, Jian Yu, Brian J. Leibowitz, Renee Fisher, Wen Hou, Donna Shields, Jan-Peter Van Pijkeren, Amitava Mukherjee, Michael W. Epperly, Anda M. Vlad, Lan Coffman, Hong Wang, M. Saiful Huq, Ravi Patel, Jason Huang, Joel S. Greenberger

Summary: Oral administration of the probiotic Lactobacillus reuteri that releases interleukin-22 (LR-IL-22) can mitigate damage to the intestine and facilitate therapeutic whole-abdomen irradiation (WAI) for ovarian cancer.

RADIATION RESEARCH (2022)

Article Oncology

Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5-and p53/PUMA-mediated cell death

Chaoyuan Kuang, Jingshan Tong, Kaylee Ermine, Manbo Cai, Fujun Dai, Suisui Hao, Francis Giles, Yi Huang, Jian Yu, Lin Zhang

Summary: The study demonstrates that NEO2734 more potently suppresses CRC cell growth than first generation BET inhibitors, inducing CRC cell apoptosis via both the intrinsic and extrinsic pathways. NEO2734 treatment simultaneously upregulates PUMA and DR5 to induce cell death, effectively suppressing CRC growth.

FRONTIERS IN ONCOLOGY (2022)

Article Biochemistry & Molecular Biology

Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction

Jingshan Tong, Xiao Tan, Suisui Hao, Kaylee Ermine, Xinyan Lu, Zhaojin Liu, Anupma Jha, Jian Yu, Lin Zhang

Summary: Targeting cyclin-dependent kinases (CDKs) has shown promising therapeutic potential against cancer. A recent study reveals that selective CDK4/6 inhibitors induce Death Receptor 5 (DR5) via p73, leading to increased sensitivity of colorectal cancer cells to therapy-induced apoptosis. This finding provides valuable insights into the anticancer mechanisms of CDKIs and their potential clinical applications in colorectal cancer.

ONCOGENE (2023)

Article Multidisciplinary Sciences

Synthetical lethality of Werner helicase and mismatch repair deficiency is mediated by p53 and PUMA in colon cancer

Suisui Hao, Jingshan Tong, Anupma Jha, Denise Risnik, Darleny Lizardo, Xinyan Lu, Ajay Goel, Patricia L. Opresko, Jian Yu, Lin Zhang

Summary: Synthetic lethality can be used to target oncogenic drivers in cancer, and in this study, it was found that WRN helicase is required for the survival of MSI CRC cells. Depletion of WRN induces p53 and PUMA, leading to apoptosis in MSI CRC cells. The vulnerability of MSI CRCs to WRN loss is mediated by p53/PUMA-dependent apoptosis. WRN depletion or treatment with ML216 suppresses the growth of MSI CRCs in vitro and in vivo in a p53/PUMA-dependent manner.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Article Biochemistry & Molecular Biology

Role of Receptor Interacting Protein (RIP) kinases in cancer

Kaylee Ermine, Jian Yu, Lin Zhang

Summary: The RIP kinase family plays a crucial role in cell survival and cell death signaling. Dysregulation of RIP kinases is associated with various pathological conditions including inflammatory diseases, neurological diseases, and cancer. Alterations of RIP kinases in cancer cells contribute to tumor progression, therapeutic resistance, and escape from immune response. Targeting RIP kinases has potential implications for cancer treatment.

GENES & DISEASES (2022)

Article Biochemistry & Molecular Biology

mTOR inhibition suppresses Myc-driven polyposis by inducing immunogenic cell death

Brian J. Leibowitz, Guangyi Zhao, Wenxin Xia, Yuhan Wang, Hang Ruan, Lin Zhang, Jian Yu

Summary: In this study, the researchers discovered that mTOR inhibition can effectively suppress the formation of intestinal polyps, reverse established polyps, and prolong the lifespan of APC(Min/+) mice. Everolimus reduces the levels of p-4EBP1, p-S6, and Myc in the polyps and induces apoptosis of cells with activated beta-catenin. This cell death is accompanied by ER stress, activation of the extrinsic apoptotic pathway, innate immune cell recruitment, and subsequent T-cell infiltration.

ONCOGENE (2023)

Article Oncology

Release of Interferon-β (IFN-β) from Probiotic Limosilactobacillus reuteri-IFN-β (LR-IFN-β) Mitigates Gastrointestinal Acute Radiation Syndrome (GI-ARS) following Whole Abdominal Irradiation

Diala F. Hamade, Michael W. Epperly, Renee Fisher, Wen Hou, Donna Shields, Jan-Peter van Pijkeren, Amitava Mukherjee, Jian Yu, Brian J. Leibowitz, Anda M. Vlad, Lan Coffman, Hong Wang, M. Saiful Huq, Ziyu Huang, Claude J. Rogers, Joel S. Greenberger

Summary: Irradiation can be an effective treatment for ovarian cancer, but its use is limited by intestinal toxicity. Strategies to mitigate toxicity are important and LR-IFN-beta, a genetically engineered probiotic, shows potential as a safe and feasible radiation mitigator. LR-IFN-beta protects the intestine, improves survival, and can potentially revolutionize OC patient management when combined with platinum/taxane-based chemotherapy.

CANCERS (2023)

Review Pharmacology & Pharmacy

Targeting Myc-driven stress addiction in colorectal cancer

Haris Saeed, Brian J. Leibowitz, Lin Zhang, Jian Yu

Summary: MYC is a proto-oncogene that plays a crucial role in the development of cancer cells. It is frequently rearranged and amplified in hematologic malignancies and is associated with cancer progression and therapeutic resistance. Activation of specific signaling pathways increases Myc levels, leading to stress adaptation, metabolic reprogramming, and immune evasion. Targeting Myc has proven challenging, but recent advances in understanding its mechanisms have opened up potential strategies for treatment, especially in colorectal cancer.

DRUG RESISTANCE UPDATES (2023)

Meeting Abstract Oncology

Restoring necroptosis in colorectal cancer cells to overcome chemotherapeutic resistance

Kaylee Ermine, Dongshi Chen, Peng Wang, Jian Yu, Lin Zhang

CANCER RESEARCH (2022)

Meeting Abstract Oncology

Unsupervised sub-cellular segmentation of complex tissue and cell samples using highly multiplexed imaging-derived a priori knowledge

Bogdan Kochetov, Phoenix D. Bell, Rebecca Raphael, Benjamin J. Raymond, Brian J. Leibowitz, Jingshan Tong, Brenda Diergaarde, Jian Yu, Reetesh K. Pai, Robert E. Schoen, Lin Zhang, Aatur Singhi, Shikhar Uttam.

CANCER RESEARCH (2022)

Article Biochemistry & Molecular Biology

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer

Hang Ruan, Brian J. Leibowitz, Yingpeng Peng, Lin Shen, Lujia Chen, Charlie Kuang, Robert E. Schoen, Xinghua Lu, Lin Zhang, Jian Yu

Summary: Mutant KRAS plays a crucial role in colorectal cancer by promoting Myc translation and Myc-dependent stress adaptation and proliferation. The combination of two FDA-approved drugs, Bortezomib and Everolimus, has been found to be highly effective against mutant KRAS colorectal cancer cells. This combination rapidly depletes Myc protein and induces cell death through various pathways. The study also shows that mutant KRAS colorectal cancer cells with elevated basal Myc and p-eIF2 alpha are more sensitive to the BR combination and exhibit characteristics of stress adaptation and cell death.

MOLECULAR BIOMEDICINE (2022)

No Data Available